A recent study has revealed that the MenB vaccine, which was introduced to protect at-risk men from gonorrhoea, offers no actual protection against the infection. Despite initial optimism based on earlier studies suggesting a potential reduction in gonorrhoea cases, the new findings indicate that vaccination does not significantly lower infection rates among men who have sex with men.
The trial, conducted in Australia, monitored nearly 600 participants over two years, showing similar rates of gonorrhoea infections in both vaccinated and unvaccinated groups. This raises critical questions about the effectiveness of the vaccine and the public health strategy surrounding its use, especially as gonorrhoea cases remain alarmingly high in the UK.
Health officials, including the UK Health Security Agency, have stated that they will continue to gather data from the ongoing vaccination programme before making any changes. However, experts are urging a reevaluation of the vaccination strategy, particularly in light of rising antibiotic-resistant strains of gonorrhoea.
As the search for an effective gonorrhoea vaccine continues, public health advocates stress the importance of traditional prevention methods, such as condom use and regular STI testing, to combat the ongoing epidemic of sexually transmitted infections in the UK.
Source: BBC News
